Sean Toenjes

Company: Aethon Therapeutics

Job title: Executive Director, Chemistry & Innovation

Seminars:

Discovery of Bispecific T-Cell Engagers Targeting Covalent Drug-Modified KRASG12C Neoantigens 2:15 pm

Development of engineered bispecific T-Cell engagers that recognize KRAS covalent inhibitor–modified peptide-MHC complexes with high affinity and specificity Companion immunotherapy approach designed to complement KRASG12C inhibitors enabling selective killing of resistant tumor cells in vitro and in vivo Cross-HLA binding and structural insights supporting broad patient coverage and the molecular basis for recognition of hapten-modified…Read more

day: Day Two